Program
GLM101
A development code. Also written as “GLM101 (Part A, Double-blind)”.
Its studies are mostly in Ataxia, led by Glycomine.
Furthest: phase 3, since Feb 6, 20253 company-led studies, 2 open or runningNext primary completion: Sep 2029 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Glycomine | 32 open or running | phase 3since Feb 6, 2025 | Aug 24, 2022 | Sep 2029phase 2 · NCT06657859 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 24, 2022First study: phase 2 study in Congenital disorder of glycosylation type 1AFirst studyNCT05549219 · 27 enrolled · United States, Spain, United Kingdom
- Oct 22, 2024Phase 2 study in Congenital disorder of glycosylation type 1ANCT06657859 · 90 planned · United States, Czechia, France and more
- Feb 6, 2025Phase 3 study in Congenital disorder of glycosylation type 1ANCT06892288 · 50 enrolled · United States, Belgium, Czechia and more
Ahead
- Sep 2029Primary completion: phase 2 study in Congenital disorder of glycosylation type 1ANCT06657859
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06892288Congenital disorder of glycosylation type 1A · United States, Belgium, Czechia and more | 3 | Active, not recruiting | Aug 5, 2026 | 50 |
| NCT06657859Congenital disorder of glycosylation type 1A · United States, Czechia, France and more | 2 | By invitation | Sep 2029 | 90 |
| NCT05549219Congenital disorder of glycosylation type 1A · United States, Spain, United Kingdom | 2 | Completed | Nov 4, 2025 | 27 |
How it is read
Names in the registry
- “GLM101”, 2 entries
- “GLM101 (Part A, Double-blind)”, 1 entry
Codes read as this program: GLM101.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.